ABHI Annual Report 2012

Association of British Healthcare IndustriesAnnual Report 2012/13

Innovative, safe & effective medical technologies

Association of British Healthcare Industries

About ABHI

“With over 240 members, ABHI leads the advocacy of the industry in order to advance access to medical technology. Our membership includes some of the leading multinational businesses in the sector in the UK right the way through to small and medium sized enterprises (SMEs).”

ABHI: Advancing Access to Medical TechnologyVision: To lead the advocacy of the UK medical technology industryMission: To champion the benefits and use of safe and effective medical technologies to deliver high quality patient outcomes

Contents01 Strategic Pillars02 Core Priorities03 Key Achievements04 Chairman and Chief Executive Round Table06 UK Market08 International10 Regulatory12 Compliance13 ABHI Groups Structure14 ABHI Board of Directors15 ABHI Staff and Membership List

Association of British Healthcare Industries 1

Advocating policies that will promote a favourable business environment for members’ organisations;

• In the UK Market: Policies that support the rapid evaluation, reimbursement and adoption of medical technologies by UK healthcare systems.

• In the International Markets: Policies to provide an effective gateway to foreign markets.

• With appropriate Regulations and Standards: Simple and smart regulation, providing patients with safe, effective, high quality and innovative medical technologies.

• With appropriate Ethics and Principles: Policies to ensure business is conducted in the right manner.

Medical technologies are the products used in the treatment and diagnosis of medical conditions.

Medical technologies range from those we are familiar with – plasters, spectacles, latex gloves, to more complex rare products such as implantable devices and complex scanners.

Medical technologies enable millions of people all over the world to live more productive and independent lives.

The UK medical technology sector employs 71,000 people and has an annual turnover of £17 billion.

“38 million people in the UK come into contact with a medical device every day.”

Strategic Pillars

Association of British Healthcare Industries2

Core Priorities

“Patients must receive the most appropriate medical technology for them in the long term, not just the cheapest”

UK MarketCommunicate industry requirements to the ‘new’ NHS:

• dedicated medical technology leadership in NHS Commissioning Board; and

• jointly agreed principles of partnership to enable NHS providers realise outcomes from medical technology.

Support successful transition of leadership and implementation mechanisms for key IHAW Tasks to NHS Commissioning Board.

InternationalCapitalise on export opportunity presented by NHS Global and Healthcare UK.

Minimise importation and regulatory market barriers in key export regions.

RegulationInfluence progress of the MDR legislative process to ensure that industry position is preserved.

Develop UDI based Implant Traceability scheme with MHRA.

ComplianceExpand industry-wide adoption of ABHI CoBP.

Launch Accreditation Scheme and gain broad NHS acknowledgement.


Key Achievements

UK MarketFollowing the creation of many new NHS structures as part of the reforms, ABHI moved quickly to build strong links and start a constructive dialogue with the NHS Commissioning Board. Through that engagement we have raised the profile of the industry, improved our understanding of the change drivers for healthcare delivery over the years to come, and critically appraised the structures of the new landscape that will affect the interaction between industry and the NHS from 2013 onwards.

We also set about playing a leadership role in the implementation of the recommendations of ‘Innovation Health and Wealth’ (IHW) as a priority. Our industry is now embedded in the delivery of IHW. ABHI has a seat at the IHW Implementation Board and we facilitated a number of secondees to lead implementation work.

Our work on innovation and NHS leadership is complemented by our activity on NHS procurement. We lobbied to ensure procurement was seen as a strategic priority for the NHS and were very pleased to see Sir Ian Carruthers leading the ‘World Class Procurement in the NHS’ review. Commercial Policy Group participants were highly instrumental in developing the ABHI position and we know that much of it resonates with the NHS. We look forward to working with the NHS in the implementation of the review.

RegulatoryOur priority for the year was to develop a clear industry position on the Revision of the Medical Device Directives (MDD) and to engage with the new Devices Division of the Medicines and Healthcare Products Regulatory Agency (MHRA), to ensure that UK Government position was aligned with industry. That activity and engagement proved successful and Government’s stance now broadly reflect our industry’s views.

ABHI appeared before the House of Commons Science and Technology Select Committee during their inquiry into the regulation of medical implants. The subsequent report agreed with many of the recommendations including the inappropriateness of a pharmaceutical style pre-market authorisation process, greater transparency in the system and significantly improving the designation and control of Notified Bodies.

InternationalABHI’s work to support industry expansion overseas continued at pace in 2012 in both trade support and policy direction. Through our export support work we took over 300 companies to the Arab Health exhibition in Dubai and to Medica, in Dusseldorf. In conjunction with the UK Trade and Investment (UKTI) , we also ran trade missions to Saudi Arabia and India to help companies gain insight and information on how to open up those markets. The ‘Export Club Seminars’ we hosted supplemented this activity providing detailed market information to over 250 industry representatives.

We set ourselves ambitious targets on policy development. The International Policy Group developed the industry position on Government support for UK exporters and this position has formed the basis of our engagement with Government. We are now fully engaged with UKTI’s new Managing Directors and Ministers.

Ethics and Compliance2012 saw ABHI introduce Guidelines on Advertising and Promotional Materials to the ABHI Code of Business Practice (CoBP). This was a well-received addition to the Code covering an area that is absent from the general advertising law in the UK.

We have also agreed the principles and operation of an Accreditation Scheme. This scheme aims to create a standard industry system that certifies personnel who are appropriately qualified to operate in clinical settings. The scheme will be launched at the start of 2013.


Chairman and Chief Executive Round Table

The year started with a maelstrom of negative publicity around regulation. The PIP implants issue was not an isolated incident, rather it revealed significant antipathy towards our regulatory system by many important stakeholders. I think that along with colleagues, notably Eucomed, we are developing a compelling industry stance that will help ensure that not only are our patients protected, they also receive timely access to innovative, life enhancing and lifesaving technologies. The fact that our Regulatory update conference in the summer was, literally, standing room only, tells you how important an issue this is for our members.Johnny Lundgren

Peter EllingworthChief Executive

Johnny LundgrenChairman

#1What were the key developments for the medical technology industry in 2012?

Alongside the media coverage surrounding regulation we also managed to make steady progress on the Innovation Health and Wealth programme and have succeeded in getting industry people embedded in the delivery of this enhanced industry input. The new NHS landscape began to take shape throughout 2012, and we took the necessary steps to begin building relationships with the new NHS leaders.Peter Ellingworth

#2The NHS reforms will take shape in 2013 – what does industry need to do to keep pace with these changes?

We have to stay connected and stay informed. Beyond the understandable turmoil surrounding reorganisation on this scale, there are some significant changes of emphasis, such as more centralisation of specialised services or the movement of Public Health outside of the NHS.Johnny Lundgren

The new NHS landscape will require a significant shift in the way the medical device industry does business. Industry will need to build strong strategic relationships with the new structures. Most importantly industry will have to align itself with the new NHS and support the deliver of improved patients outcomes on reduced budgets.Peter Ellingworth

5Association of British Healthcare Industries

#3What do you see as ABHI’s key role as NHS changes take shape?

#4What are the key challenges facing industry in 2013?

The Association is the main conduit for delivering this information to our members and we must continue to do so. I believe our UK market updates are the best available anywhere in this regard. Innovation, Health and Wealth continues to offer significant opportunities, but with no fewer than 29 Task and Finish groups currently operational, the Association has a key role in signposting the critical areas.Johnny Lundgren

ABHI has an important role in supporting our members to work effectively alongside the new structures. To do this we need to undertake a number of activities. Firstly we must map out and explain to industry what the new NHS looks like and how it will operate. Secondly we must engage with key leaders to ensure the NHS understands how to work with industry from the very top right the way down. Peter Ellingworth

Beyond understanding the NHS changes and continuing to get across our messages on Regulation, we will see the effects of austerity measures continuing to bite. In this climate it will be critical to not only make sense of what continues to be a complex and confusing procurement landscape, but also to ensure we can demonstrate the value our industry and our products truly brings.Johnny Lundgren

The key challenges for 2013 are twofold – firstly industry needs to form productive relationships with the new NHS. This will involve developing different relationships with different people. Secondly, industry must engage policy makers to ensure that the European regulator system for medical devices continues to deliver innovation in a timely manner.Peter Ellingworth


UK Market

Andy TaylorExecutive Director, Healthcare Policy

Nishan SuntharesCommercial and Market Access & Regulation

Judith MellisSenior Manager, UK Market Affairs

Miles AylingDirector of InnovationNHS Commissioning Board

“We need to do things differently. We need to transform the way we deliver services, and innovation is the answer. It is vital that procurement in the NHS is based on outcomes, not just cost, and is responsive to creative ideas. We have the potential to deliver the highest quality patient care, offer value for money and make the NHS a better place to do business. Our collective challenge is to work together to realise that potential.”

ABHI’s objectives in 2012 focused on three areas, building on the work in previous years:

• ProcurementABHI sought a review of NHS procurement that would be ambitious in scale and linked to the intent in Innovation Health and Wealth . To that end we were delighted when Sir Ian Carruthers announced he would lead the ‘World Class Procurement in the NHS’ review.

The ABHI Commercial Policy Group took the lead in mobilising industry effort to support Sir Ian’s work. The Group developed a comprehensive industry position to address key strategic issues: the need to clarify the landscape, re-define the role of NHS Supply Chain and focus on purchasing for outcomes.

Much of the industry position resonates with the findings of the Review Team in their engagement with other stakeholders.

Naturally there are also areas of non-alignment. These will need to be managed, and ABHI looks forward to the publication of the Review and working with the Review Team to lead implementation of recommendations.

• Building a clear and structured relationship with the NHS Commissioning Board, following the passage of the Health & Social Care Act into law and the emergence of plans for an entirely new set of structures in the NHS in England from 2013.

• Taking a leadership role in implementation of the recommendations of Innovation, Health and Wealth, published in December 2011.

Health & Social Care ActThe implementation of the Health & Social Care Act was described by Sir Ian Carruthers, at the ABHI conference on 28 November 2012, as changing the course of a super-tanker and its crew at the same time. The NHS Commissioning Board was largely a skeleton operation during 2012 and, although these early relationships were positive, no regular arrangements are yet in place. The Board’s director for innovation, Jim Easton, was a key contact for the Association during most of 2012. He was chief guest at a dinner for members hosted by ABHI in October, where he welcomed the industry’s preparedness to respond to the new challenges that the NHS is facing. Leadership for innovation has now shifted to Sir Bruce Keogh, medical director for the Commissioning Board, who has a clear view of the significance of medical technology in service delivery and improvement.

At a local level, it is clear that some Clinical Commissioning Groups (CCGs) will be ready, but perhaps a small minority. For the rest, 1 April 2013 will find them as a ‘work in progress’. None of this will help reduce the cost to serve for suppliers. Many of the key issues for members relate to what the Board will do at national level and especially through the proposals to harmonise specifications for specialised services across England. Members broadly welcomed the Board’s proposals for this, although in some cases they mark a big change from the current variety of practice around the country. Understandably, the weight given to evidence, marks a new benchmark for access to the NHS for higher risk devices, so it is vital to get the detail right as ABHI commented in our response to the consultation.


Another key issue for the new commissioning system is access to reimbursement which in England means tariff or PbR. From 2013/14, tariff development will have to be agreed between the NHS Commissioning Board, which will lead on design of currencies, and Monitor, which will lead on pricing. Statutory consultation procedures will apply and this will make the annual cycle altogether longer and more drawn out. Members were also concerned about the difficulty in getting new technologies recognised within tariff, principally through exclusions to tariff. Without exclusions, innovative products may simply not be recognised by the NHS in a consistent way that allows procedures to cover their costs.

Innovation, Health and WealthOn Innovation, Health & Wealth, the Implementation Board has supervised the progress of the 26 work streams set out in the publication of December 2011. Peter Ellingworth, ABHI’s Chief Executive, is a member of this Board. Some of the smaller tasks in the report were completed relatively quickly but a number required much longer term changes in the operation of NHS systems and are still underway, with links to the development of the new NHS Commissioning Board. The top themes for medical technology concern:

• the reduction of variation and strengthening compliance in uptake of technologies, principally those approved by NICE;

• creating a system to deliver innovation; and

• incentives and investment for uptake.

The key activities for reducing variation have involved publication of a ‘scorecard’ showing how uptake of a number of technologies varies across the country, together with the creation of a ‘NICE Implementation Collaborative’. This brings together a range of bodies, including ABHI, to devise new ways of supporting the uptake of technologies, with pilots now in development.

To create a new system to ensure that innovation is implemented in the NHS, is leading to the development of ‘academic health science networks’ to bring together all NHS bodies with universities and industry. These networks aim to ‘transform the identification, adoption and spread of innovations and best practice, through the alignment of healthcare delivery, teaching, research, education and training and partnership with industry’. It is clear that the intent here is to involve industry. ABHI is working towards arrangements which are in keeping with our Code of Business Practice whilst enabling good information to be channelled between these geographically based entities and industry, through participation on various types of advisory boards.

#1 Innovation improves and extends lives. Innovation in the NHS is about making a real and tangible difference to the lives of millions. Across the NHS, countless patients bear witness to the power of great ideas.

#2Innovation connects and drives quality and productivity in the NHS. The NHS faces a challenging future with increasing financial pressures and continually increasing demand for improved quality of services. It is clear that the NHS must raise its game to develop more high-quality and cost-effective interventions if it is to keep improving.

#3Innovation will support the UK economy. The NHS remains a major investor and wealth creator in the UK, and in science and engineering in particular. Innovation is not just about the future of the NHS and health and social care, it is about the future of our country’s economy too.


International

Grahame WalkerTerumo UK

“ABHI provide us with an invaluable source of information that supports Terumo to work more effectively. Our engagement with ABHI’s working groups and our interaction with the secretariat have supported our work in the UK. The medical device industry needs a strong, collective voice with a well connected, well informed organisation speaking for us.”

ABHI worked throughout 2012 to ensure that the support offered by the UK government is aligned to the strategic needs of the medical technology industry. Our work prior to 2012 had focussed on identifying the areas where ABHI can have the most impact. These fell into three categories- international policy; trade promotion and intelligence and opportunities.

Trade Promotion Activity The development of trade fairs, missions, export conferences, seminars and partnering has continued at a pace during the year. 2012 has proved to be very successful in connecting members to customers overseas. A number of new products and services were implemented including a more proactive public relations initiative which provided increased visibility and coverage for both members and ABHI. We saw the first series of active scoping and trade missions overseas to gauge opportunity in key markets and deliver introductions to customers and potential partners.

We also continued to develop our relationship with the reorganised UKTI. ABHI has identified the key UKTI pathways that are pivotal to our industry and has actively engaged with those new structures to strengthen relationships support and influence the way trade services are delivered and strategy is formed. Government are now embracing a closer relationship with industry bodies and increased use of trade associations as partners. ABHI is now seen as a key partner to UKTI and has met with UKTI’s Chief Executive and Senior

Leadership Team on a number of occasions to engage in dialogue over better, more efficient and productive Government – Industry working.

Through this improved engagement and relationship, and as a result of successful delivery in a variety of UKTI supported activities in 2012 ABHI will be taking part in a pilot scheme as an ‘enhanced delivery partner’. This will see ABHI taking on additional work in the delivery of practical trade services on behalf of UKTI and our industry and an expanded programme of activity in our key markets for 2013/14.

Paul BentonDirector, International

Liz CarringtonManager, Events

Sarah IzonExhibitions Executive


International Policy ABHI is now consistently feeding into the Department of Business Innovation &Skills (BIS) all the policy work that is taking place around market access issues. Information submitted by ABHI to BIS has been used to inform and influence work on the development of Free Trade Agreements and used by BIS to speak to the EC and to inform and brief UK Ministers travelling overseas.

Our parliamentary engagement has seen ABHI and its partners develop the Trade & Investment All Party Parliamentary Group (APPG). Members of the ABHI International Policy Group now sit on the Advisory Board and have an active role in influencing its agenda. ABHI has had a regular and productive dialogue with the Chair of the Group Margot James MP, Vice Chair Conservative Party, who also acts as Permanent Parliamentary Secretary to the Minister for UK Trade & Investment, Lord Green.

Intelligence and OpportunitiesThroughout 2012 ABHI has met with key opinion leaders across the Middle East and from across our key markets. A series of receptions and engagement activities have provided members with the opportunity to meet with Health Ministers and opinion leaders from around the world. Early in the year ABHI met with the Minister of Health from the United Arab Emirates and Jordan, leaders from the Health Committee in Qatar and in September ABHI met with the Minister of Health from Oman. International Policy Group members hosted delegations from the Chinese State Food and Drug Administration in October including the Chinese Head of Devices and his colleagues to raise issues around duration and cost of registrations in China. This work is set to continue and increase throughout 2013.

Throughout 2012 we have worked with the Managing Director of NHS Global feeding in industry views to the development of this new joint Government unit and taking an active role providing insight into potential key markets overseas. ABHI will continue to engage with this new unit as it develops throughout 2013 identifying areas of opportunity and activity, which will assist industry.


Regulatory

Mike KreuzerExecutive Director, Technical and Regulatory

Clive PowellSenior Manager, Compliance and Regulation

Graeme TunbridgeHead of Medical Devices EU Policy

“The publication of the proposals to revise the medical devices directives this year is a significant milestone. The MHRA is negotiating the new legislation on behalf of the UK Government and an open and constructive dialogue with ABHI is absolutely essential to this process.”

ABHI and European Industry supports change to the Regulatory System2012 has been a challenging year in Regulatory Affairs. Our key priority has remained the need to influence the processes around the revision of the medical device regulatory system. This has meant working closely with the MHRA and Eucomed as well as the European Union (EU) Commission and indeed others who might influence the eventual outcome. We entered the year with a fair degree of consensus about how the system should be reformed, all parties recognising the need for change in a number of areas following the PIP scandal. However, it soon became evident that there was increasing pressure for a more radical approach.

Science and Technology Select Committee InquiryIn March we were advised that we would be required to provide written and verbal evidence to the Science and Technology Parliamentary Select Committee looking specifically at the regulatory system as a result of the PIP scandal. This was only the second time in ABHI history that we have had to respond to a Select Committee and in the event this turned out to be a successful exercise resulting in a well balanced report justifying many of the arguments put forward by industry.

Formal ProposalFour years of consultation culminated in the September publication of the Formal Proposal from the EU Commission for a Medical Device Regulation (MDR). This is a

proposal for a single Regulation replacing the Medical Device Directives and Active Implantable Medical Devices which, when adopted, will have direct effect on Member States. The proposal has now entered the Co-Decision Process which must result in agreement between Parliament, the Member States (the Council) and the Commission. The process could take two years or more and it could be a further two years before the Regulation applies i.e. becomes mandatory. This slow pace is an unfortunate feature of European legislation due to the process described above and the number of Member States (27) needing to agree.

Critics of the current system were not slow to point out the length of time needed for any reform to take effect. The EU Commission to their credit introduced some immediate measures, proposed as far back as February, which will in effect bring forward some of the changes in the new Regulation.


The Formal Proposal itself contained only a few surprises. In July the European Parliament had voted narrowly for a Resolution calling for pre-market authorisation of implants. This is non-binding but has resulted in the introduction of a clause requiring ‘added scrutiny’ of Class III devices as a political counterweight to the resolution. Industry is concerned that the proposal involving examination of Notified Body Dossiers pre CE marking is excessively bureaucratic and will not bring any improvement to patient safety. An alternative scrutiny process will be proposed by industry early in 2013. Apart from this high-profile example, there are a wide range of detailed changes to the system in the MDR Proposal and these have to be worked through with great care by the Technical Policy Group in ABHI and then taken to Eucomed to feed into the debate at EU level.

We all have to recognise that the eventual outcome will at best give us a new regulatory framework based on the same principles but which will be tougher and more costly for industry. At worst we could end up with a system which would severely restrict innovation and which could be a serious brake on the development of small and medium sized companies. In general, industry is fully supportive of most of the proposed changes and recognises the need for reform of many aspects of the current system in particular tighter control of Notified Bodies, better post market surveillance and greater transparency.


Compliance

There has been a considerable amount of compliance activity during 2012; with much of it behind the scenes work on projects that will be launched in 2013. By contrast it has been fairly quiet in relation to the ABHI CoBP and The Bribery Act. We still await the first case to be dealt with by the ABHI Code of Business Practice Complaints Adjudication Panel. Despite this, we did appoint a new Panel this year as well as a new Chairman – Mr Bruce Ash who has a longstanding involvement with ABHI in a number of areas.

Activity around The Bribery Act was just as quiet. There have as yet been no cases involving corporate entities so it is difficult to judge the Act’s long-term effects. The ABHI Legal Issues and Compliance Committee continues to monitor the situation and ABHI has written to the new Serious Fraud Office Chief Executive to re-establish contact with the regulator following his predecessor’s departure.

Accreditation SchemeThe principal area of activity during the year has been to set up a scheme for company personnel to apply for a photo ID card to demonstrate that they have undergone suitable training to allow them to be present in acute and/or critical care areas in hospitals. The aim is to provide a scheme that will promote best practice to the industry, provide the NHS (and the private sector) with a no-cost system for checking that company representatives are appropriately trained and to ensure that standards are in place that patients would expect.

The scheme will be open to the whole industry, not just ABHI members, and in 2013 the focus will be on gaining recognition by all parties so that carrying the card and requesting it becomes an ingrained behaviour for the industry and health care providers respectively. High-level endorsement of the scheme has been sought from Government.

Guidelines on Advertising & Promotional MaterialsThe guidelines were implemented as part of the ABHI Code in April and will apply to all materials from 1 January 2013: A transition period of nine months was allowed for pre-existing materials to be brought into line. There had been an expectation that introduction of this new section of the code would result in some complaints for the ABHI Panel to review; however, so far this has not been the case – hopefully this indicates good levels of compliance out in the marketplace.

Ethical Compliance Logo SchemeThe pilot phase of the Logo Scheme reached its conclusion in the autumn. A number of companies have joined the scheme, either as ABHI or Eucomed members and the next stage is to engage in more promotional activity to encourage more to participate. From 2013 there will be an annual fee for joining and a light-touch process will be set up to systematically review companies’ compliance with the scheme’s requirements. Eucomed will look for more of its member associations to launch their own national versions of the scheme so that it is recognised across the EU.

Expanding ComplianceA key principal of ABHI’s programme is to encourage greater recognition of the importance of ethical compliance across the industry. Systems are being put in place to allow companies from outside the direct membership to sign up to the ABHI Code, raising standards across the industry. This will be one of the key activities for 2013.


ABHI Groups Structure

• Commercial• International• Legal Issues & Compliance Committee• Public Affairs• Technical

• Communications• HCAI• PbR• Sterilisation and Microbiology• Supply Chain and eBusiness• Health Technology Assessment

• Advanced Wound Management• Cardiac Rhythm Management• Elimination of Sharps• Neurosciences• Orthopaedic• Procedure Packs• Spine• Surgical Instruments• Vascular

Board of Directors

Operating Committee

Policy Groups

Working Groups Special Interest Sections


ABHI Staff on the Board

ABHI Board of Directors

Johnny Lundgren ChairmanVice President, North West Europe, Becton Dickinson

Tim CouttsUK Group General Manager Boston Scientific Limited

Philip KennedyManaging DirectorEschmann Holdings Limited


Mike KreuzerExecutive Director, Technical and Regulatory


Shah Fayyaz Vice Chairman Managing Director, Timesco of London Ltd

Simon Talbot Managing Director, P3 Medical

Jackie FieldingRegional Vice PresidentUK & IrelandMedtronic

Harry Keenan General ManagerBaxter Healthcare Ltd

Sandra LawrencePublic Affairs & Health Policy ManagerStryker UK Ltd

James UrieSales and Marketing DirectorMediplus Ltd

Alison YatesHR DirectorMD&D UK/Ire/NardicsJohnson & Johnson


ABHI Staff List Membership List


Mike Kreuzer, OBEExecutive Director, Technical and Regulatory


Paul BentonDirector, International

Clive PowellSenior Manager, Compliance and Regulation

Nishan SuntharesCommercial and Market Access & Regulation

Judith MellisSenior Manager, UK Market Affairs

Daniel JonesDirector, Communications

Sarah IzonExhibitions Executive

Liz CarringtonManager, Events

Linette IronsManager, Facilities

Angela JefferyPA to Chief Executive and Membership Development Manager

Esther MannoukasAccounts Administrator

Miruna SpiridonCommunications Assistant

Chike EduputaUK Market Intern

Ian CranstonAccountant and Company Secretary

Andy VaughanConsultant, Standards Policy

3M Health Care Limited

AA Algeo LtdAbbott Medical OpticsAbbott VascularAccentus Medical plcAdvanced Bionics UK LtdAerocrine LtdAerte LtdAIM Consulting LtdAirsonett UK LimitedAlbert Browne LtdAlcon Laboratories (UK) LimitedAlgotec Research and Development LimitedAltomed LtdAltrax Group LtdAmerican Medical Systems UK LtdAmtac Certification ServicesAnetic Aid LtdAngioDynamics UK LtdAnsell (UK) LtdApaTech LtdApos Medical UK LtdApplied Medical Technology LtdArjoHuntleigh UK LtdArjoHuntleigh, Diagnostic Products DivisionArnold & Porter (UK) LLPAspire Sales Force Development LimitedAvental Ltd

BB. Braun Medical LtdBailey Instruments LtdBaker & McKenzie SolicitorsBakers Instrument Brokers LtdBard LtdBaremaBausch & Lomb UK LtdBaxter Healthcare LtdBecton Dickinson UK LtdBedfont Scientific LtdBiocompatibles UK LtdBiomet UK Healthcare LTDBiotronik UK LtdBircham Dyson Bell LLPBird & Bird LLPBM Polyco LtdBolton Surgical LtdBoston Scientific LtdBristowsBritish Dental Trade AssociationBrowne Health Care LtdBSi

CCalea UK LtdCameron Health UKCarl Zeiss LimitedCaterham Surgical Supplies LtdCeramTecCirrus Healthcare ProductsClement Clarke International LtdClinimax LtdCMS Cameron McKennaCompliance Hub Limited

Conceptus Medical LtdConvaTec LtdCook (UK) LtdCorin LtdCovidien (UK) Commercial LtdCyberonics Europe S.A.

DDDC Dolphin LtdDeltex MedicalDePuy InternationalDePuy UKDixons Surgical Instruments LtdDLA Piper UK LLPDonawa Lifescience ConsultingDTR Medical LtdDurbin plc

EEdwards Lifesciences LtdEschmann EquipmentEuromedica LtdEUSA Pharma (Europe) Ltdev3 LtdEvexar Medical LtdExcellentcare Medical LtdExmoor InnovationsExmoor Plastics Ltd

FFannin UK Ltd, Surgical DivisionFasken Martineau LLPFertility Focus LtdField Fisher Waterhouse LLPFresenius Kabi LtdFull Support Healthcare Ltd

GGalbraithWight LtdGalil Medical UK LtdGAMA Healthcare LtdGlobus Medical UK LtdGriffiths & Nielsen Medical DivisionGS1 UKGSK Consumer HealthcareGuerbet Laboratories Ltd

HH W Andersen Products LtdHaag Streit UK LtdhanoverHarvey Medic LLPHealth Edge Consumables LtdHealth Technology Solutions Spain s.l.Healthlogistics.co.uk LtdHeraeus MedicalHologic UK LtdHorton Ruston PooleHospira UK LtdHull Associates


Membership List continued

IIntegra NeuroSciences LtdIvor Shaw Ltd

JJMH Publishing LtdJohn Weiss & Son LtdJohnson & Johnson Medical LtdJRI Orthopaedics LtdJuzo UK Ltd

KK2 Medical Systems LtdK2M UK LtdKapitex Healthcare LtdKarl Storz Endoscopy (UK) LtdKimal PlcKLS Martin UK Ltd

LLabCold LtdLiDCO LtdLifecare Hospital Supplies LtdLifescan UK – a Johnson & Johnson CompanyLloyds Register Quality Assurance LtdLombard Medical Technologies Plc, Cardiovascular DivisionLyall Willis & Co Ltd

MMalaysian Rubber Export Promotion CouncilManagement Forum LtdMathys Orthopaedics LtdMatOrtho LtdMatrix Marking LtdMax Medical Products LtdMDM Medical LtdMecobo LtdMedacta UK LimitedMedartis LtdMedeuronet UK LtdMedi UK LtdMedical Wire & Equipment Co (Bath) LimitedMedicare Colgate LtdMedicom Group LtdMediplus LtdMeditec International England LtdMeditech Systems LtdMedtronic LimitedMedvance LtdMercuri Urval LimitedMi3 LtdMirage Health Group LtdMolnlycke Health Care LtdMoor Instruments LtdMorgan LewisMovianto UK Ltd

NNew Co-Ordinates LtdNorgine Pharmaceuticals LtdNuVasive UK Ltd

OOlympus KeymedO’Mara Medical SuppliesOPTIC (UK)Ortho Solutions LtdOrthofix LimitedOrthovita UK LtdOwen Mumford Ltd

PP3 Medical LtdPall MedicalPan Globus LtdParburch Medical Developments LtdPDI EuropePentax (UK) LtdPera Innovation LtdPfizer Consumer Healthcare LtdPhagenesis LimitedProcter & Gamble Technical Centres LtdProplink Medical (Europe) LtdPuricore Sterilox EndoscopyPWB Health UK Ltd

QQSpine LtdQuanta Fluid Solutions LtdQuintiles ConsultingQuotec Ltd

RRayner Intraocular Lenses LtdReam Surgical LtdRenfrew Group International LtdRenishaw Diagnostics LtdRenishaw PlcRichard Wolf UK LtdRoberts Surgical Healthcare LtdRSA Group

SS Murray & Co LtdSaharan Trading Company LtdSarstedt LimitedScanTrack Healthcare LtdSchulke and Mayr UK LtdScient’x (UK) LtdScotmed LtdSDMASGS United Kingdom LtdSimmons & Simmons LLPSmart Use LtdSmith & NephewSmithKline Beecham LtdSmiths Medical International LtdSMS Technologies LtdSNR Denton UK LLPSorin Group (UK) LtdSouth Western Surgical LtdSovereign Medical LtdSphinx Medical LtdSpineVision Ltd

Squire Sanders (UK) LLPSt Jude MedicalStanmore Implants Worldwide LtdStar Syringe LtdSterigenics UK LtdSterilin LtdSTERIS LtdSTOK UK LtdStryker UK LtdSurgi C LtdSurgical HoldingsSurgical Instrument Group Holdings LtdSurgins Surgical LtdSwann-Morton LtdSymmetry MedicalSymmetry Medical Cheltenham LtdSynergus ABSynthes LtdSystagenix Wound Management International Ltd

TTaylor WessingTerumo UK LtdThe Tinnitus Clinic LtdTimesco of LondonTissue Regenix LtdTissue Science Laboratories LtdTomorrow Options – Microelectronics LtdTornier UK LtdTÜV SÜD Product Service Ltd

UUK MAM LtdUK Medical LtdUnderwriters Laboratories LtdUnirose Medical Ltd

VVerathon MedicalVerna Group Ltd

WW L Gore & Associates (UK) LtdWalker MorrisWelch Allyn (UK) LtdWright Medical UK Ltd

XXiros Ltd

ZZimmer Ltd

Association of British Healthcare Industries

FSC LOGO TO GO HERE

Association of British Healthcare Industries250 Waterloo RoadLondon SE1 8RDT 020 7960 4360F 020 7960 [email protected]

www.abhi.org.uk

ABHI Annual Report 2012

Documents

Transcript of ABHI Annual Report 2012